Drug
Dv281
Dv281: highest development phase Phase 1, developed by Dynavax Technologies. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Dynavax Technologies
Trials
| Drug | Phase | Indication |
|---|---|---|
| DV281 NCT03326752 | Phase 1 | Advanced Non Small Cell Lung Cancer |
Latest
No recent events.
Follow Dv281 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.